JP2024516073A5 - - Google Patents
Info
- Publication number
- JP2024516073A5 JP2024516073A5 JP2023557140A JP2023557140A JP2024516073A5 JP 2024516073 A5 JP2024516073 A5 JP 2024516073A5 JP 2023557140 A JP2023557140 A JP 2023557140A JP 2023557140 A JP2023557140 A JP 2023557140A JP 2024516073 A5 JP2024516073 A5 JP 2024516073A5
- Authority
- JP
- Japan
- Prior art keywords
- independently selected
- formula
- compound
- compound according
- nitrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163162468P | 2021-03-17 | 2021-03-17 | |
| US63/162,468 | 2021-03-17 | ||
| PCT/US2022/020482 WO2022197758A1 (en) | 2021-03-17 | 2022-03-16 | Heteroaryl inhibitors of plasma kallikrein |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024516073A JP2024516073A (ja) | 2024-04-12 |
| JP2024516073A5 true JP2024516073A5 (enExample) | 2025-03-25 |
Family
ID=81328275
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023557140A Pending JP2024516073A (ja) | 2021-03-17 | 2022-03-16 | 血漿カリクレインのヘテロアリール阻害剤 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240228488A1 (enExample) |
| EP (2) | EP4308230A1 (enExample) |
| JP (1) | JP2024516073A (enExample) |
| KR (1) | KR20240004296A (enExample) |
| CN (1) | CN117355521A (enExample) |
| AU (1) | AU2022240596A1 (enExample) |
| BR (1) | BR112023018619A2 (enExample) |
| CA (1) | CA3208243A1 (enExample) |
| MX (1) | MX2023011014A (enExample) |
| WO (1) | WO2022197758A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3765459A1 (en) | 2018-03-13 | 2021-01-20 | Shire Human Genetic Therapies, Inc. | Substituted imidazopyridines as inhibitors of plasma kallikrein and uses thereof |
| EP4031245A1 (en) | 2019-09-18 | 2022-07-27 | Takeda Pharmaceutical Company Limited | Heteroaryl plasma kallikrein inhibitors |
| DK4031547T3 (da) | 2019-09-18 | 2024-09-09 | Takeda Pharmaceuticals Co | Plasmakallikreininhibitorer og anvendelser deraf |
| CN117396473A (zh) * | 2021-03-17 | 2024-01-12 | 武田药品工业株式会社 | 血浆激肽释放酶的咪唑并吡啶基抑制剂 |
| BR112023018619A2 (pt) | 2021-03-17 | 2023-11-28 | Takeda Pharmaceuticals Co | Inibidores de heteroaril de calicreína plasmática |
| EP4590663A2 (en) * | 2022-09-21 | 2025-07-30 | Takeda Pharmaceutical Company Limited | Synthesis of cyclopropane carboxylic acids |
| EP4735442A1 (en) * | 2023-06-29 | 2026-05-06 | Theranib Inc. | IMIDAZO[1,2-alpha]PYRIDINE COMPOUNDS FOR USE IN TREATING CANCER AND INFLAMMATORY DISEASES AND METHODS TO PREPARE SAID COMPOUNDS |
| CN117069662A (zh) * | 2023-10-17 | 2023-11-17 | 峰成医药科技(天津)有限公司 | 一种4,6-二氯-2-（二氟甲基）嘧啶的合成方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4911920A (en) | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
| FR2588189B1 (fr) | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | Composition pharmaceutique de type a transition de phase liquide-gel |
| JP2594486B2 (ja) | 1991-01-15 | 1997-03-26 | アルコン ラボラトリーズ インコーポレイテッド | 局所的眼薬組成物 |
| US5212162A (en) | 1991-03-27 | 1993-05-18 | Alcon Laboratories, Inc. | Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions |
| US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
| GB201421088D0 (en) * | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | New enzyme inhibitors |
| US9815853B2 (en) * | 2015-06-12 | 2017-11-14 | Global Blood Therapeutics, Inc. | Bridged bicyclic kallikrein inhibitors |
| EP3765459A1 (en) | 2018-03-13 | 2021-01-20 | Shire Human Genetic Therapies, Inc. | Substituted imidazopyridines as inhibitors of plasma kallikrein and uses thereof |
| BR112023018619A2 (pt) | 2021-03-17 | 2023-11-28 | Takeda Pharmaceuticals Co | Inibidores de heteroaril de calicreína plasmática |
-
2022
- 2022-03-16 BR BR112023018619A patent/BR112023018619A2/pt unknown
- 2022-03-16 EP EP22716137.9A patent/EP4308230A1/en active Pending
- 2022-03-16 MX MX2023011014A patent/MX2023011014A/es unknown
- 2022-03-16 KR KR1020237034887A patent/KR20240004296A/ko active Pending
- 2022-03-16 JP JP2023557140A patent/JP2024516073A/ja active Pending
- 2022-03-16 CA CA3208243A patent/CA3208243A1/en active Pending
- 2022-03-16 WO PCT/US2022/020482 patent/WO2022197758A1/en not_active Ceased
- 2022-03-16 CN CN202280022472.XA patent/CN117355521A/zh active Pending
- 2022-03-16 EP EP25179074.7A patent/EP4585265A3/en active Pending
- 2022-03-16 US US18/550,306 patent/US20240228488A1/en active Pending
- 2022-03-16 AU AU2022240596A patent/AU2022240596A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024516073A5 (enExample) | ||
| JP2022548696A5 (enExample) | ||
| JP2024510503A5 (enExample) | ||
| JP2021524440A5 (enExample) | ||
| AU2017254523B2 (en) | Compounds and compositions for treating conditions associated with NLRP activity | |
| JP2020525442A5 (enExample) | ||
| JP4344235B2 (ja) | タキソール増強剤化合物 | |
| DE60126344T2 (de) | Isoindolimid-verbindungen, zusammensetzungen und verwendungen | |
| JP2023518286A5 (enExample) | ||
| JP2021527126A5 (enExample) | ||
| JP2017052786A5 (enExample) | ||
| JP2017538689A5 (enExample) | ||
| EP4069683A1 (en) | Dimeric compounds as sting agonists | |
| JP2019013227A5 (enExample) | ||
| JP2013506715A5 (enExample) | ||
| JP2018536634A5 (enExample) | ||
| RU2007105350A (ru) | 3-(гетероарилокси)-2-алкил-1-азабициклоалкильные производные, как лиганды альфа-7-nachr (никотиновых ацетилхолиновых рецепторов), предназначенные для лечения заболеваний центральной нервной системы | |
| AR104417A2 (es) | Compuestos de tiadiazolidina, procedimiento para su preparación, composición farmacéutica que lo compone y usos de dichos compuestos | |
| JP2020528937A5 (enExample) | ||
| JP2006504710A5 (enExample) | ||
| JP2024510502A5 (enExample) | ||
| JPS60228477A (ja) | ２‐アルコキシ‐ｎ‐（１‐アザビシクロ［２，２，２］オクト‐３‐イル）ベンズアミド類およびチオベンズアミド類 | |
| JP2024512497A5 (enExample) | ||
| TW200906829A (en) | 5,6-dihydro-1H-pyridin-2-one compounds | |
| RU2005137360A (ru) | Органические соединения |